China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has struck a partnership with compatriot firm ReviR Therapeutics, an artificial-intelligence (AI) and gene tech-powered start-up. The collaboration aims to utilize ReviR’s in-house developed AI drug research and development (R&D) platform and targeted RNA technology to conduct research into urogenital system tumors and related major diseases.
Partnership Details
Specifically, as per the agreement, designed to improve patient prognosis, Asieris will use ReviR’s innovative RNA controlling technology BindeR and SpliceR to identify and develop RNA-targeted cancer therapies. This strategic move is expected to enhance the development of novel treatments for urogenital cancers and other significant diseases.
ReviR Therapeutics: AI and RNA Technology
Founded in 2021, ReviR Therapeutics describes itself as based in both California, the US, and Shenzhen, China. The emerging biopharma is focused on the research and development of small targeted RNA molecules against tumors and inheritable diseases. The company combines AI computing and high-throughput drug discovery technology via its VoyageR AI drug discovery platform, aiming to address “undruggable” targets at the RNA level. ReviR’s product pipeline is focused on the central nervous system, oncology, and other inheritable diseases.
Asieris: Focus on Urogenital Cancer
Established in 2010, Asieris focuses on developing, manufacturing, and commercializing first-in-class drugs in the urogenital cancer and other major disease areas. This partnership with ReviR Therapeutics is expected to accelerate Asieris’ efforts in bringing innovative treatments to patients suffering from urogenital cancers and related conditions.-Fineline Info & Tech
